Agilent Technologies Inc has announced the successful conclusion and key outcomes of their 2021 Executive Technical Summit, held virtually on February 12.

The summit was established to provide a forum for Agilent and its partners to discuss recent trends in the industry, new challenges faced by customers, and how Agilent can partner with them to provide solutions that are customised to meet these challenges.

In preparation for this year's summit, Agilent interacted with its external partners as well as opinion leaders in the pharma industry, sharing some of their key products capable of addressing the needs and challenges of the pharma/biopharma industry today. 

Samir Vyas, Country Manager, Agilent India, said, ”The Executive Technical Summit has been a promising platform for enabling open discussions with our expert team around the actions we’ve taken and customer feedback on new methods and technologies.”

Maria Angeles Diaz, Agilent EMEAI Sales Vice President and General Manager, added, ”Our commitment to customers is to provide trusted answers to solve their key challenges, so getting the opportunity to talk about new emerging trends, understand how the situation of 2020 has impacted their business models, and hear their perspective about the industry for the mid/long term is an essential enabler to our mutual success.”

Topics discussed at the summit included: ways to ensure accurate analysis of biomolecules and vaccines using the Agilent 1290 Bio LC; strategies for increasing productivity and compliance through automation of data management with SLIMS; meeting upcoming regulatory requirements in materials identification using tools such as Vaya Raman; and orthogonality in materials characterisation (solid state) by LDIR.